Nuvectis Pharma Financials
| NVCT Stock | USD 5.49 0.03 0.55% |
Nuvectis |
Please note, the imprecision that can be found in Nuvectis Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Nuvectis Pharma. Check Nuvectis Pharma's Beneish M Score to see the likelihood of Nuvectis Pharma's management manipulating its earnings.
Nuvectis Pharma Stock Summary
Nuvectis Pharma competes with Replimune, Lyra Therapeutics, Kronos Bio, Gossamer Bio, and Olema Pharmaceuticals. Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company was incorporated in 2020 and is based in Fort Lee, New Jersey. Nuvectis Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US67080T1088 |
| CUSIP | 67080T108 |
| Location | New Jersey; U.S.A |
| Business Address | 1 Bridge Plaza, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.nuvectis.com |
| Phone | 201 614 3150 |
| Currency | USD - US Dollar |
Nuvectis Pharma Key Financial Ratios
Nuvectis Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nuvectis Pharma's current stock value. Our valuation model uses many indicators to compare Nuvectis Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nuvectis Pharma competition to find correlations between indicators driving Nuvectis Pharma's intrinsic value. More Info.Nuvectis Pharma is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Nuvectis Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Nuvectis Pharma Systematic Risk
Nuvectis Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Nuvectis Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Nuvectis Pharma correlated with the market. If Beta is less than 0 Nuvectis Pharma generally moves in the opposite direction as compared to the market. If Nuvectis Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Nuvectis Pharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Nuvectis Pharma is generally in the same direction as the market. If Beta > 1 Nuvectis Pharma moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Nuvectis Pharma is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Nuvectis has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Nuvectis Pharma's financials are consistent with your investment objective using the following steps:- Review Nuvectis Pharma's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Nuvectis Pharma's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Nuvectis Pharma's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Nuvectis Pharma's stock is overvalued or undervalued.
Nuvectis Pharma January 18, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Nuvectis Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Nuvectis Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Nuvectis Pharma based on widely used predictive technical indicators. In general, we focus on analyzing Nuvectis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Nuvectis Pharma's daily price indicators and compare them against related drivers.
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 75.91 | |||
| Value At Risk | (10.50) | |||
| Potential Upside | 9.69 |
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.